• Viemed filed annual report for fiscal year ended Dec. 31, 2025, outlining strategy to grow patient volumes through technology-enabled, home-based respiratory and chronic care programs.
• Operations continued nationwide, with company serving patients in all 50 US states.
• Business remained centered on respiratory care, with home ventilation positioned as core revenue driver alongside oxygen therapy and sleep apnea treatment.
• Product mix faced potential demand shifts tied to updated Medicare coverage criteria for noninvasive ventilation in chronic respiratory failure related to COPD, finalized June 9, 2025.
• Board authorized share repurchase program on March 4, 2026, allowing buybacks of up to 1,930,131 common shares through March 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viemed Healthcare Inc. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.